LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

By LabMedica International staff writers
Posted on 17 Apr 2025
Print article
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected but also imposes significant financial strain on healthcare systems due to the costs associated with dialysis and organ transplants. However, early diagnosis can significantly alter a patient’s course of treatment, offering better options and potentially halting or slowing the progression of the disease. The challenge lies in the fact that current kidney function tests typically require visits to a laboratory, expensive equipment, skilled personnel, and several days to obtain results. These requirements make routine screenings difficult, particularly for those in rural and Indigenous communities. Now, researchers have created an innovative tool that could revolutionize how kidney disease is diagnosed, especially in underserved areas.

A team of researchers from the University of Manitoba (Winnipeg, Canada) has developed a device known as the uCR-Chip, a low-cost, portable diagnostic tool designed to make kidney function testing faster, more convenient, and widely accessible. The results are available in less than seven minutes, and the test does not require specialized laboratory equipment. Their research, published in Microsystems & Nanoengineering, showcases how this device could play a crucial role in enhancing early detection and improving outcomes for individuals living with chronic kidney disease (CKD). The uCR-Chip addresses the challenges of current testing methods by utilizing a color-based chemical reaction to measure creatinine, a key biomarker of kidney health, from a small urine sample. Since it does not require advanced lab equipment, it can be used directly in health clinics or mobile healthcare settings.

The uCR-Chip has the potential to relieve pressure on healthcare systems by identifying kidney issues at earlier stages, thereby reducing the number of patients who progress to more advanced stages of disease. This could lead to fewer patients requiring costly treatments such as dialysis or transplants, allowing for more effective management with early interventions. In many rural, remote, and Indigenous communities, where access to advanced diagnostic equipment is limited, the uCR-Chip offers a portable, cost-effective alternative that could greatly improve access to vital testing. As healthcare systems worldwide seek affordable solutions to manage chronic diseases, innovations like the uCR-Chip offer not just hope, but tangible solutions that bring life-saving diagnostics to those who need them most.

“Traditional lab test can take days and may delay diagnosis,” said Dr. Francis Lin who led the research team. “Our new test method will lead to faster, more accessible and reliable diagnostic results to prevent irreversible kidney damage.”

Related Links:
University of Manitoba

Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.